Diabetes decisions — 2025

The Board granted service connection for diabetes mellitus as due to herbicide exposure, but remanded the issue of service connection for bilateral hearing loss.

The Veteran is granted special monthly compensation (SMC) based on the need for regular aid and attendance due to his service-connected disabilities.

The Board granted a 40 percent rating for diabetes mellitus and service connection for hypertension as secondary to the Veteran's service-connected diabetes.

The Board granted service connection for seborrheic dermatitis and remanded the claims for asthma, chronic fatigue syndrome, diabetes mellitus type 2, fibromyalgia, GERD, OSA, hemorrhoids, diarrhea, bilateral hearing loss, and tinnitus for further development.

The Board denied an earlier effective date for PTSD and major depressive disorder, denied service connection for colon polyps, type II diabetes, sinusitis, and chronic bronchitis, and granted service connection for allergic rhinitis, sleep apnea, and erectile dysfunction. Five neuropathy conditions were remanded for further development.

The Board granted service connection for multiple conditions, including ischemic heart disease with coronary artery disease, Type II diabetes mellitus, and Parkinson's disease, effective from October 20, 2017.

The Board granted service connection for Non Proliferative Diabetic Retinopathy with macular edema secondary to diabetes mellitus and denied the claims for a right shoulder condition, right upper extremity neuropathy, and skin cancer.

The Board granted service connection for diabetes mellitus type II as secondary to the Veteran's service-connected disabilities and increased ratings of 10 percent were granted for irritable bowel syndrome (IBS) and tinea versicolor, while denying a compensable rating for allergic rhinitis and hemorrhoids.

The Board remands the claims for service connection for diabetes, sickle cell anemia, and tinnitus due to insufficient evidence regarding the Veteran's failure to report for scheduled examinations.

The Board granted an effective date of October 7, 2014, for coronary artery disease and January 6, 2020, for diabetes mellitus Type II. The remaining issues are remanded.

The Board granted a rating of 40 percent for diabetes mellitus type 2, as the Veteran's condition required one or more daily insulin injections and regulation of activities.

The Board remands the claims for service connection for cardiovascular disease, pulmonary hypertension, GERD, and diabetes mellitus type II due to a pre-decisional duty to assist error with regard to the October 2023 VA examinations and opinions.

The Board granted service connection for several disabilities, including left thumb, left wrist, right hip, back, and sciatic nerve conditions, but denied service connection for diabetes mellitus.

The Board granted a 30 percent disability rating for diabetic nephropathy beginning February 1, 2024.

The Board granted service connection for diabetes mellitus type II and hypertension, both presumed to be due to exposure to certain herbicides during the Veteran's service in South Korea.

Service connection for the cause of the Veteran's death, due to cirrhosis of the liver, is granted.

The Board granted service connection for sleep apnea as secondary to the Veteran's service-connected hypertension and persistent depressive disorder with unspecified anxiety disorder and neurocognitive disorder, but remanded other claims related to diabetes, peripheral neuropathy, headaches, lumbar spine disability, radiculopathy, left ankle disorder, chronic fatigue, prostate cancer residuals, erectile dysfunction, and more.

The Board remands the claim for further development, specifically to determine whether the Appellant is considered the surviving spouse and to obtain an adequate medical opinion regarding the Veteran's cause of death.

The Board denied the veteran's claims for increased ratings for diabetes mellitus, headaches, and a psychiatric disability.

The Board granted service connection for coronary heart disease and diabetes type II under the PACT Act due to presumed in-service exposure to herbicide agents.